NC
ALNY icon

Nexthera Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Nexthera Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-86,293
Closed -$11M – 41
2017
Q4 		$11M Buy
86,293
+6,521
+8% +$819K 2.02% 16
2017
Q3 		$9.37M Sell
79,772
-25,228
-24% -$2.15M 2.41% 13
2017
Q2 		$8.38M Buy
+105,000
New +$6.71M 3.65% 14
2017
Q1 		– Sell
-165,000
Closed -$6.18M – 37
2016
Q4 		$6.18M Buy
+165,000
New +$6.91M 3.62% 11

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Nexthera Capital's ALNY Position: Q1 2018 in Review

Nexthera Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2018, closing a stake of 86,293 shares — an estimated $11M sold.

Nexthera Capital first reported a position in ALNY in Q4 2016 and held it in 4 quarters. The position peaked at $11M in Q4 2017. 292 funds tracked by Wall St. Rank hold ALNY as of Q1 2018.

  • Nexthera Capital reported no remaining Alnylam Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Nexthera Capital sold 86,293 Alnylam Pharmaceuticals shares in Q1 2018, an estimated $11M.
  • Nexthera Capital first reported a position in Alnylam Pharmaceuticals in Q4 2016 and held it in 4 quarters.
  • Nexthera Capital's Alnylam Pharmaceuticals position peaked at $11M in Q4 2017.
  • 292 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2018.

Based on Nexthera Capital's 13F filing for Q1 2018, filed 15 May 2018.